329 related articles for article (PubMed ID: 36131561)
21. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
22. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
[TBL] [Abstract][Full Text] [Related]
23. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for immunotherapy response in head and neck cancer.
Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A
Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128
[TBL] [Abstract][Full Text] [Related]
25. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy.
Kang JJ; Ko A; Kil SH; Mallen-St Clair J; Shin DS; Wang MB; Srivatsan ES
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188827. PubMed ID: 36309124
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.
Blaszczak W; Barczak W; Wegner A; Golusinski W; Suchorska WM
Med Oncol; 2017 Apr; 34(4):60. PubMed ID: 28315228
[TBL] [Abstract][Full Text] [Related]
27. Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
Moreira J; Tobias A; O'Brien MP; Agulnik M
Drugs; 2017 May; 77(8):843-857. PubMed ID: 28382569
[TBL] [Abstract][Full Text] [Related]
28. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
29. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
31. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.
Cassell A; Grandis JR
Expert Opin Investig Drugs; 2010 Jun; 19(6):709-22. PubMed ID: 20415598
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
[TBL] [Abstract][Full Text] [Related]
33. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
35. EGFR-targeted therapies in the post-genomic era.
Xu MJ; Johnson DE; Grandis JR
Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
[TBL] [Abstract][Full Text] [Related]
39. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
40. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
